CITATION REVIEW EXERCISE
1. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of
doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012
Jun;29(2):761-7. doi: 10.1007/s12032-011-9829-8. Epub 2011 Feb 6. PMID: 21298497.
2. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD,
Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little
evidence of improvement over the past 30 years. Cancer. 2012 Oct 12. doi: 10.1002/cncr.27819. [Epub ahead of
print] PMID: 23065954.
3. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR,
Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. A phase I trial of the oral,
multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res. 2008 Aug
1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. PMID: 18676756.
4. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Enhancement of radiation response with bevacizumab. J
Exp Clin Cancer Res. 2012 Apr 26;31(1):37. [Epub ahead of print] PMID: 22538017.
5. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken
M, Jagannath S. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients
with advanced multiple myeloma. Leuk Lymphoma. 2009 Apr;50(4):559-65. doi: 10.1080/10428190902748971.
PMID: 19373653.
6. Lera RF, Burkard ME. High Mitotic Activity of Polo-like Kinase 1 Is Required for Chromosome Segregation and
Genomic Integrity in Human Epithelial Cells. J Biol Chem. 2012 Dec 14;287(51):42812-25. doi:
10.1074/jbc.M112.412544. Epub 2012 Oct 27. PMID: 23105120.
7. Bradley KA, Zhou T, McNall-Knapp RY, Jakacki RI, Levy AS, Vezina G, Pollack IF. Motexafin-Gadolinium and
Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood: A Children's Oncology Group Phase 2
Study. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e55-60. doi: 10.1016/j.ijrobp.2012.09.004. Epub 2012 Oct
22. PMID: 23092726.
8. Titz B, Kozak KR, Jeraj R. Computational modelling of anti-angiogenic therapies based on multiparametric
molecular imaging data. Phys Med Biol. 2012 Oct 7;57(19):6079-101. doi: 10.1088/0031-9155/57/19/6079. Epub
2012 Sep 13. PMID: 22972469.
9. Adhikarla V, Jeraj R. An imaging-based stochastic model for simulation of tumour vasculature. Phys Med Biol.
2012 Oct 7;57(19):6103-24. doi: 10.1088/0031-9155/57/19/6103. Epub 2012 Sep 13. PMID: 22971525.
10. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen
HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in
recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan;24(1):220-5. doi:
10.1093/annonc/mds245. Epub 2012 Aug 16.PMID: 22898037.
11. Hu YY, Kwok AC, Jiang W, Taback N, Loggers ET, Ting GV, Lipsitz SR, Weeks JC, Greenberg CC. High-cost imaging
in elderly patients with stage IV cancer. J Natl Cancer Inst. 2012 Aug 8;104(15):1164-72. doi:10.1093/jnci/djs286.
Epub 2012 Jul 31. PMID: 22851271.
12. Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weekly ixabepilone in men with metastatic
castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin
Cancer. 2012 Jun;10(2):99-105. doi: 10.1016/j.clgc.2012.01.009. Epub 2012 Mar 3. PMID: 22386239.
13. Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C, DiPersio J.
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic
syndrome (MDS). Ann Hematol. 2012 Jan;91(1):33-8. doi: 10.1007/s00277-011-1240-1. Epub 2011 May 3. PMID:
21538061.
14. Grudzinski JJ, Burnette RR, Weichert JP, Jeraj R. Dosimetric effectiveness of targeted radionuclide therapy based
on a pharmacokinetic landscape. Cancer Biother Radiopharm. 2010 Aug;25(4):417-26.
doi:10.1089/cbr.2009.0754. PMID: 20735205.
15. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of
cancer-testis antigens in prostate cancer. Cancer Res. 2011 Nov 1;71(21):6785-95. doi: 10.1158/0008-5472.CAN11-2127. Epub 2011 Aug 31. PMID: 21880588.
16. Watkins Bruner D, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H,
Bentzen S, Kachnic L, Berk L. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile
dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG
0215. J Sex Med. 2011 Apr;8(4):1228-38. doi: 10.1111/j.1743-6109.2010.02164.x. Epub 2011 Jan 14. PMID:
21235716.
17. Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA. Rapamycin inhibits cell proliferation in type
I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol. 2010
Dec;119(3):579-85. doi: 10.1016/j.ygyno.2010.08.025. Epub 2010 Sep 21. PMID: 20863555.
18. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer
are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 2008 Sep 30;1:47. doi:
10.1186/1755-8794-1-47. PMID: 18826610.
19. Ritter MA. Prognostic and predictive markers in radiation therapy: focus on prostate cancer. Cancer Treat Res.
2008;139:97-114. Review. PMID: 18236713.
20. Tomé WA, Jaradat HA, Nelson IA, Ritter MA, Mehta MP. Helical tomotherapy: image guidance and adaptive dose
guidance. Front Radiat Ther Oncol. 2007;40:162-78. Review. PMID: 17641508.